$43.58
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Country

FR

CEO

Mr. Paul Hudson

IPO date

2002

Employees

74,846

ISIN

FR0000120578

Key stats

Open

$43.90

Volume

4.11M

Market cap

$103.90B

Prev. close

$43.90

Impl / hst vl

-

Open interest

$0.00

$43.24

Day’s Range

$44.50

$40.89

52W Range

$49.42

Valuation

72
Valuation score
Undervalued
P/E
7.43
P/S
1.28
P/B
1.25
Current ratio
1.01
Debt / Equity
0.20
ROE
17.02%
Gross margin
72.09%
Income growth
-19.34%
FCF growth
-1,909.68

Jun

3

Dividends

The last payment date was Jun 3, 2026

Div. per Share

$2.77

Div. Yield

5.51%

Payout Ratio

-

Div. Growth YoY

11.65%

Analysts estimates

Consensus rating
Hold

The average rating from top 12 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$55.69
The top 27 analysts forecasts that 12-month price may increase by 27.80%, with a low of $33.12 and a high of $67.65
$33.12
Low
$55.69
Avg
$67.65
High
Current price

Earnings

Q1 ‘26 revenue
$12.85B
Q1 ‘26 net income
$1.85B
Revenue
Net income
Previous EPS
$2.15
Estimate EPS
$2.19
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply